AMENDMENT NO. 3 TO AMENDED AND RESTATED DEVELOPMENT AND COMMERCIALIZATION AGREEMENTDevelopment and Commercialization Agreement • August 9th, 2024 • Insulet Corp • Surgical & medical instruments & apparatus
This Amendment No. 3 to the Amended and Restated Development and Commercialization Agreement ("Amendment") is dated as of March 20, 2024 ("Effective Date"), by and between Insulet Corporation ("Insulet") and Abbott Diabetes Care Inc. ("ADC").
CERTAIN INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS (I) NOT MATERIAL AND (II) IS THE TYPE THAT THE COMPANY TREATS AS PRIVATE AND CONFIDENTIAL. OMISSIONS ARE MARKED *** AMENDMENT NO. 4 to the AMENDED AND RESTATED DEVELOPMENT AND...Development and Commercialization Agreement • August 9th, 2024 • Insulet Corp • Surgical & medical instruments & apparatus
This Amendment No. 4 to the Amended and Restated Development and Commercialization Agreement (“Amendment”) is dated as of the 27th day of June, 2024 (“Effective Date”), by and between Insulet Corporation (“Insulet”) and Abbott Diabetes Care Inc. (“ADC”).
